window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : January 19, 2026

  • News
  • About Us
Contact Us

mirikizumab

  • Chronic diseases,Pharmaceuticals and therapeutics,Regulatory Affairs

    NICE backs Lilly’s mirikizumab for Crohn’s disease treatment

    The National Institute for Health and Care Excellence (NICE) has [...]

    September 10, 2025
  • Biologics & Biosimilars,Clinical Development,Patient Centricity,Regulatory Affairs

    NICE recommends Mirikizumab for moderately to severely active Crohn’s Disease after biologic failure

    Mirikizumab is now recommended by NICE for routine NHS use [...]

    July 14, 2025
  • Clinical Trials,Drug Development,Patient Centricity,Regulatory Affairs

    NICE backs mirikizumab for treatment-resistant Crohn’s disease

    The National Institute for Health and Care Excellence (NICE) has [...]

    May 30, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Veristat names Kim McLean Boericke as CEO to drive next phase of clinical research growtheristat names Kim McLean Boericke as CEO to drive next phase of clinical research growth
    Categories: Biotech, Clinical Development, Clinical studies, Clinical Trials, Healthcare leadership, Movers & Shakers, Rare Diseases
  • Will Edwards appointed CEO as Astoriom expands international storage and biorepository operations
    Categories: Biomanufacturing, CDMOs & Manufacturing, Healthcare leadership, Movers & Shakers, Pharmaceuticals and therapeutics
  • CombinAbleAI to be acquired by insitro to expand AI drug discovery platform
    Categories: Artificial Intelligence, Biotech, Drug Development, Mergers & Acquisitions, Technology and platforms
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top